Journal Scans
Poor Response to Second-Line Kinase Inhibitors in CML Patients With Multiple Low-Level Mutations, Irrespective of Their Resistance Profile
Sensitive Mutation Analysis Identifies Additional Poor-Risk CML
WT Parker, M Ho, HS Scott, TP Hughes, S Branford
20111130
2011 Dec 30
Blood
Poor Response to Second-Line Kinase Inhibitors in CML Patients With Multiple Low-Level Mutations, Irrespective of Their Resistance Profile
Blood. 2011 Dec 30;[Epub Ahead of Print], WT Parker, M Ho, HS Scott, TP Hughes, S Branford
TAKE-HOME MESSAGE
Abstract
Abstract
Specific imatinib-resistant BCR-ABL1 mutations (Y253H, E255K/V, T315I, F317L, F359V/C) predict failure of second-line nilotinib and/or dasatinib therapy in CML patients. However, around 40% of chronic phase patients without these resistant mutations also fail. We investigated whether sensitive mutation analysis could identify other poor-risk subgroups. Analysis was performed by direct sequencing and sensitive mass-spectrometry on 220 imatinib-resistant patients before commencing nilotinib or dasatinib....
